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Background: Macrophage infiltration and expression of matrix metalloproteinase-9 (MMP-9) are markers of high-risk
atherosclerotic carotid plaques and strong indicators of plaque instability. Use of statins is associated with a decreased risk
of stroke and reportedly improves stability of atherosclerotic plaques, but available data addressing the mechanism of this
effect are conflicting.
Methods: We retrospectively analyzed data from 94 consecutive patients with internal carotid artery stenosis who
underwent carotid endarterectomy. Excised plaques underwent systematic quantitative immunohistochemical analysis to
determine the percentage of macrophage area and the percentage of MMP-9 area. Associations between percentage of
macrophage area and percentage of MMP-9 area and use of statins and cerebrovascular disease were examined by
univariate and multivariate analysis.
Results: We found significantly higher values of percentage of macrophage area and of MMP-9 area in recently
symptomatic (n  26) compared with asymptomatic (n  68) internal carotid artery stenoses: median (IQR) percentage
of macrophage area was 2.29 (1.53-4.129) vs 0.53 (0.27-0.96) and percentage of MMP-9 area was 0.61 (0.36-0.89) vs
0.08 (0.02-0.27; both P< .0005). Patients treated with statins (n 49) showed lower percentage values of macrophage
area and MMP-9 area than untreated patients: the percentage of macrophage area was 0.54 (0.31-1.18) vs 1.03
(0.57-2.08; P  .01) and percentage of MMP-9 area was 0.06 (0.02-0.22) vs 0.36 (0.16-0.62; P < .0005). These
associations between statin treatment and percentages of macrophage area and MMP-9 area did not change after
controlling for symptomatic cerebrovascular disease and the effects of other potential confounders in multivariable
analysis.
Conclusions: Our results confirm the value of percentage of macrophage area and percentage of MMP-9 area as markers
of plaque instability and provide further evidence to support the hypothesis that statins reduce inflammatory responses
and thereby stabilize carotid atherosclerotic plaques. ( J Vasc Surg 2008;47:513-22.)Ischemic strokes are frequently caused by thromboem-
boli that arise from carotid atherosclerotic plaques.1 In-
flammatory processes in general, and monocyte-derived
macrophages in particular, play a critical role in plaque
progression and plaque destabilization.2-4 Several studies
have reported an increase in the number of macrophages in
symptomatic internal carotid artery (ICA) plaques,5-7 al-
though in one study such a difference was not observed.8
Continued macrophage infiltration is believed to pro-
mote inflammatory signaling and contribute to enhanced
proteolysis of the extracellular matrix bymatrix metallopro-
teinases (MMPs). Matrix metalloproteinase-9 selectively
degrades gelatin, collagen type IV and V, thereby weaken-
ing the protective fibrous cap that covers plaque lesions and
making plaques more prone to rupture.9 Higashikata
et al10 found that patients with symptomatic ICA stenoses
had elevated levels of MMP-9, but notMMP-1 orMMP-3,
in rupture-prone areas of plaque compared with stable
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plaque destabilization.
Several randomized and placebo-controlled trials have
demonstrated that statins reduce strokes as well as transient
ischemic attacks (TIAs) in patients with coronary artery
disease (CAD), regardless of their initial cholesterol lev-
els.11-14 The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial showed that after high-
dose therapy with atorvastatin, the risk of stroke was re-
duced even in patients without active CAD.15 These find-
ings suggest that statin-related therapeutic effects involving
cervical and cerebral arteries may be independent of cho-
lesterol control, consistent with observations that statins
mediate numerous pleiotropic effects, including anti-
inflammatory effects that may influence plaque stability.16-18
It has been suggested that changes in the levels of
macrophage infiltration and expression of MMP-9 can be
used as markers of the anti-inflammatory effect of statin
treatment on carotid plaques. Some studies have reported
reduced MMP-9 levels with statin treatment,19,20 and in a
small but prospective cohort analysis, Crisby et al21 ob-
served reduced numbers of macrophages in symptomatic
ICA stenoses after therapy with 40mg of pravastatin. In the
latter study, however, levels of MMP-9 expression were
unaffected. Moreover, an analysis of carotid plaques from
nearly 400 patients found that macrophage infiltration was
not reduced but enhanced in patients with preoperative
statin treatment and that MMP-9 expression was unaf-
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tration, MMP-9, and statin treatment in carotid plaques
remains unclear.
In the present study, we used a systematic quantitative
histochemical method applied to standardized immunohis-
tochemically processed sections of carotid plaques to exam-
ine the relationship between macrophage infiltration and
MMP-9 expression on the one hand, and statin treatment
and the occurrence of symptomatic CVD on the other. We
also evaluated sections for morphologic features of indirect
plaque instability, such as plaque rupture, large lipid core,
surface thrombus, and intraplaque hemorrhage, and corre-
lated them with the immunohistochemical staining results.
METHODS
Patients. We screened 101 consecutive patients with
high-grade ICA stenosis and planned carotid endarterec-
tomy (CEA). Seven patients with nonatherosclerotic steno-
sis (eg, radiation-induced stenosis, restenosis) were ex-
cluded, leaving 94 patients. The study took place during a
period of 27 months. Each patient’s cardiovascular risk
factors and medication history (drug types, dosage, dura-
tion) were documented. Fasting blood samples were col-
lected on the day of surgery. Study patients were classified
as having either asymptomatic or symptomatic ICA stenosis
according to the North American Symptomatic Endarter-
ectomy Trial criteria (NASCET).23 Approval for this study
was obtained from the institutional ethics committee. In-
formed consent was obtained from all patients before en-
rollment in the study.
Tissue preparation, immunohistochemistry, and
histopathology. After surgery, ICA plaque specimens
were immediately rinsed in 0.9% sodium chloride solution
before fixation in a 4.5% (w/v) buffered formalin solution
for 24 hours. Specimens were subsequently decalcified
using ethylenediaminetetraacetate (EDTA) solution (0.5
mol/L) for 24 hours. Thereafter, specimens were cut in
3-mm-thick consecutive transverse sections, each cut be-
ginning from the proximal end of the lesion. All sections
were cut, consecutively, from the same plaque and were
ordered, as indicated, from the proximate to distal end of
the lesion, and sections were from the full extent and length
of the surgically excised lesion using similar methods to
those published by others.24 Numbered sections were em-
bedded side-by-side in paraffin using standard procedures.
Altogether, an average of five transverse sections per patient
were processed.
From these paraffin blocks, thin (4-m) sections were
obtained for immunohistochemical detection of CD68
(KP-1, 1:75 dilution Dako, Glostrup, Denmark) and
MMP-9 (15W2, 1:25 dilution; Novocastra, Newcastle
upon Tyne, United Kingdom). Detection of CD68 was
done according to the manufacturer’s instructions using a
streptavidin-biotin system (LSAB kit, Dako). The immu-
nohistochemical staining for detection of MMP-9 was
done according to the manufacturer’s instructions using
the universal immunoenzyme polymer method (Histofine
Simple Stain AP MULTI, Nichirei, Tokyo, Japan). Forboth stainings, alkaline phosphatase was used as the re-
porter enzyme and Fast Red chromogen (Sigma-Aldrich, St
Louis, Mo) was used as the staining agent. For both stain-
ings, color development was examined under a light micro-
scope and stopped by immersing the slides in Tris buffer.
Nuclear counterstaining was obtained using hematoxylin
and the slides were mounted with aqueous mounting me-
dium. All specimens were stained using the same proce-
dures. Tonsil biopsy specimens were used as a positive
control for CD68, and liver biopsy specimens were used as
a positive control for MMP-9.
Staining and processing of all slides was accomplished
during three consecutive days to control for staining vari-
able (eg, quality and condition of solutions, materials, and
room temperature) such that there is little or no variability
in the staining conditions. So, for example for CD68 stain-
ing, up to 40 slides where stained in one session.
Additional transverse sections from paraffin blocks
were taken and stained with elastin van Gieson and hema-
toxylin and eosin.
Immunohistochemical stainings were evaluated and
quantified by two independent observers (H. K., N. A.) and
an independent histopathologist (W. W.) who were
blinded to the patient’s medical or drug history. Analysis of
morphologic features of indirect plaque instability was
done by H. K., and the results were analyzed by an inde-
pendent pathologist (W. W.). Morphologic features were
graded as defined by Redgrave et al.24 Cap rupture was
recorded if there was clear communication between lipid
core and lumen with a break between in the fibrous cap.
Large lipid core was defined as amorphous material con-
taining cholesterol crystals that occupied 50% of thick-
ness of plaque or 25% of total cross section area. In
addition, a giant lipid core was defined when definition of
large lipid core was fulfilled in three cross sections or50%
of all cross sections and at least one lipid core occupied
75% of total cross-section area. Intraplaque hemorrhage
was recorded if there was an area of erythrocytes within the
plaque causing disruption of plaque architecture. Surface
thrombus was defined as organized collection of fibrin and
red blood cells in the vessel lumen.
Images were acquired using a motorized Axioplan 2
imaging microscope system and an Axiocam Hrc digital
camera in conjunction with Axiovision 4.2 software at50
optical magnification. High-resolution images were merged
from multiple overlapping images using a motorized mi-
croscope stage and the “stitching” technique of the soft-
ware module Panorama. A mean number of 43 single
images per section were joined (see Fig 1). Semiautomatic
measurements were made using the software module
AutoMeasure (all hardware and software products were
from Carl Zeiss, Göttingen, Germany). All images were
taken with the same standardized settings, including expo-
sure time, filter settings, brightness, and contrast.
A color threshold mask was defined for the area of
macrophage infiltration, the area of MMP-9 staining, as
well as the total section area, to compute the percentage of
red-colored immunostaining in relation to the total section
ach.
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Macrophages were present in dense, often confluent, infil-
trates, making the delineation of individual cells impossible.
Cell nuclei surrounded by red staining were considered to
be a part of macrophage-positive areas. This analysis did not
distinguish between a concentrated accumulation or scat-
tered distribution of macrophages and MMP-9. The same
threshold was applied to all stainings.
We determined the size of the area occupied by CD68-
positive cells planimetrically and calculated the total per-
centage of macrophage-rich areas in relation to the com-
bined surface area measurements of all cross sections per
specimen (PMA-sum of macrophage-rich areas of all cross
sections in m2  100/sum of surface area of all cross
sections in m2). The percentage of MMP-9 area (PMMP-
9A) was calculated in the same manner (Fig 1).
Statistical analysis. Categoric data are presented as
numbers and percentages (%), and continuous numeric
data are presented as median and interquartile range (IQR)
because all numeric variables were not normally distrib-
uted. Unadjusted associations between statin treatment
and other baseline variables and between baseline variables
and PMA/PMMP-9A were analyzed using the 2 test or
the Fisher exact test where appropriate for categoric vari-
ables and the Mann-Whitney U test for continuous nu-
meric variables. Associations between statin treatment and
PMA/PMMP-9A adjusted for CVD and other baseline
variables for which a significant effect was found in the
univariate analysis (P  .2 for inclusion) were analyzed by
multiple logistic regression analysis (stepwise backward,
P  .1 for exclusion) using PMA/PMMP-9A as binary
outcomes (above or below the median), because the as-
sumptions for multiple linear regression were not met.
Significance of associations was calculated with the likeli-
hood ration test for heterogeneity. A value of P  .05 was
Fig 1. Quantification of the content of macrophages a
plaques.Panel a,High-resolution image during processin
joined using the Panorama software stitching techniqu
quantitatively analyze the image (50 original magnific
immunoreactivity is shown at high resolution (400 orig
the process of specific signal detection at400 original m
section areas as well as the areas of macrophage infiltrat
areas compared with the total section area (see Evaluation
of the area occupied by CD68-positive cells planimetricall
in relation to the combined surface area measurements of
of all cross sections in m2  100/sum of surface area o
positive areas was determined by a corresponding approconsidered statistically significant.To study the reproducibility of the assessments of PMA
and PMMP-9A, two independent observers evaluated all
stainings. Interobserver agreement was assessed by calcu-
lating the intraclass correlation coefficient (ICC). Because
interobserver agreement was equivalent for both PMA and
PMMP-9A (ICC 97%), the mean values of the two
independent measurements for each case were used for
statistical analysis. Statistical analyses were performed with
the SPSS 12.0 (SPSS Inc, Chicago, Ill) and Stata 9.2
(StataCorp, College Station, Tex) software packages.
RESULTS
Patient characteristics. Patient data are summarized
in Table I. According to the NASCET criteria, 26 of 94
patients (28%) were characterized as symptomatic and 68
(72%) as asymptomatic. The median time between the
ischemic event and CEA was 17.5 days (IQR, 10-28 days).
At the time of enrollment in the study, 49 patients (52%
of all patients) were being treated with statins. All were
taking lipophilic statins, including atorvastatin in 34 (69%),
simvastatin in 14 (29%), and fluvastatin in one (2%). The
median duration of therapy was 12 months overall, 7
months for atorvastatin, and 24 months for simvastatin.
The patient on fluvastatin had been taking the medication
for 12 months. Statins were prescribed to 37 of 68 patients
(54%) with asymptomatic ICA stenosis and 12 of 26 (46%)
with symptomatic ICA stenosis (P .5). Eight patients had
become symptomatic during statin therapy. Four patients
received statins after an ischemic event but before CEA; the
median duration of therapy was 34.5 days.
Of the variables listed in Table I, only the value for
apolipoprotein B (Apo B) was significantly different be-
tween symptomatic and asymptomatic patients, with lower
values in patients with symptomatic ICA stenosis. The
grade of stenosis as well as the use of other medications
atrix metalloproteinase-9 within atherosclerotic carotid
ngle, overlapping images, framed in blue and green, were
a result, we were able to zoom in on the details and
). Panel b, Representative cross-section of macrophage
agnification).Panel c,Representation of Fig 2, b during
fication. A color threshold mask was defined for the total
detect the percentage of red-colored immunostaining
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oss sections per specimen (sum of macrophage-rich areas
cross sections in m2). The total percentage of MMP-9nd m
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tors, calcium antagonists, angiotensin receptor inhibitors,
-blockers, nitrates, diuretics, insulin, oral antidiabetics)
was not significantly different between patients with asymp-
tomatic and symptomatic ICA stenosis or between patients
with or without statin therapy (data not all shown). In the
statin group, significantly higher proportions of patients
had hyperlipidemia and hypertension. Statin-treated pa-
tients had lower median concentrations of cholesterol,
low-density lipoprotein (LDL), and Apo B, consistent with
successful treatment of hyperlipidemia, but did not differ
from untreated patients in other blood test results or risk
factors (Table I). Notably, all patients had normal levels of
C-reactive protein, indicating that no confounding acute
inflammatory disease was present.
Semiquantitative immunohistochemistry and
histopathology. We first validated our immunohisto-
chemical analysis for detection of macrophages and
MMP-9. Fig 2 shows representative sections that were
stained with antibodies for macrophages and MMP-9,
which were readily detected by red staining. Appropriate
staining of macrophages and MMP-9 was confirmed using
tonsil and liver biopsy specimens, respectively, as positive
controls. Overall, the median PMA was 0.86 (IQR, 0.42-
1.53) and the median PMMP-9A was 0.16 (IQR, 0.05-
0.46).
Significantly lower values of PMA and PMMP-9A were
Table I. Baseline characteristics of patients from statin and
Variablesa Statin (n 
Symptomatic ICA stenosis 12 (25)
Grade of ICA stenosis, % 90 (80-90)
Age, years 68 (58.5-7
Males 31 (63)
Coronary artery disease 25 (51)
Myocardial infarction 10 (20)
Peripheral vascular disease 15 (31)
Hypertension 49 (100)
Hyperlipidemia 49 (100)
Diabetes mellitus 16 (33)
Body mass index, kg/m2 26.8 (24.4-2
Smoking habits, pack years 0 (0-35)
Ex-smokers 9 (18)
Alcohol abuse 3 (6)
Family history of vascular diseasesd 27 (55)
Serology
Cholesterol, mg/dL 157 (133.5-
Triglycerides, mg/dL 180 (123-22
LDL, mg/dL 78 (54.5-9
HDL, mg/dL 45 (38-49)
C-reactive protein, mg/dL 0.3 (0.1-0.8
Apolipoprotein A1, mg/dL 123 (106.5-
Apolipoprotein B, mg/dL 78 (65-90)
Lipoprotein (a), mg/dL 11.6 (4.9-51
LDL, Low-density lipoprotein; HDL, high-density lipoprotein.
aCategoric variables are presented as number (%), continuous variables med
bBy 2 test, P  .05 was significant.
cMann-Whitney U test; P  .05 was significant.
dCerebrovascular, cardiac, or peripheral vascular disease among first and secfound in asymptomatic compared with symptomatic ICAstenosis (both P  .0005; Fig 3). The difference between
asymptomatic and symptomatic patients seemed to be
more pronounced for MMP-9 staining compared with
macrophage infiltration. Among 26 patients with symp-
tomatic stenosis, there was weak evidence for a correlation
between time from symptoms in days and PMA (Spearman
, 	0.38; P  .06), with higher PMA values in patients
with more recent symptoms. There was no evidence for a
correlation between time from symptoms and PMMP-9A
(Spearman ,	0.03; P .09). Five of the group of patients
with asymptomatic ICA stenosis had a history of carotid-
territory ischemic events older than 120 days related to
their ICA stenosis. Values of PMA and PMMP-9A were
lower in these five patients than in patients with a symp-
tomatic ICA stenosis.
The assessment of associations between morphologic
features of indirect plaque instability (Fig 4) and symptom-
atic stenosis and the relationships between those features
and PMA and PMMP-9A are summarized in Tables II and
III. Plaque rupture, large and giant lipid core, and plaque
hemorrhage were all associated with symptomatic stenosis
and with higher values of PMA. Significantly higher
PMMP-9A values were found in ruptured plaques and in
plaques with giant cores.
Associations between statins and inflammatory
markers. Median PMA and PMMP-9A values were two-
fold and sixfold lower, respectively, in the 49 patients
statin groups
No statin (n  45) P
14 (31) .47b
85 (80-90) .07b
64 (59.5-71.5) .36b
35 (78) .12b
25 (56) .66b
8 (18) .75b
16 (36) .61b
40 (89) .02b
19 (42) .0005b
16 (36) .77b
25.6 (23.7-28.6) .41c
0 (0-41.5) .46c
10 (22) .64b
6 (13) .24b
20 (44) .30b
) 192 (172.5-215) .0005c
177 (119-254.5) .69c
118 (92-133) .0005c
43 (37.5-48.5) .69c
0.2 (0.1-0.45) .55c
122 (109-133.5) .87c
95 (86-116.5) .0005c
22.3 (6.8-43.7) .25c
terquartile range).
egree relatives.no
49)
5.5)
8.7)
181.5
4.5)
5.5)
)
136)
.4)
ian (inreceiving statins before CEA than in the 45 untreated
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(MMP-9). Panel a, Representative cross section shows specific immunoreactivity for macrophages. Anti-CD68
staining results in a granular cytoplasmic staining with red dye precipitates (100 original magnification). Panel b,
Positive control shows specific immunoreactivity for macrophages in a tonsil biopsy specimen. Panel c, Representative
cross section shows specific immunoreactivity for MMP-9. The color pattern resulting from anti-MMP-9 staining is
cytoplasmic (100 original magnification) Panel d, Positive control shows specific immunoreactivity for MMP-9 in a
liver biopsy specimen.Fig 3. Characteristic morphologic features of indirect plaque instability. Panel a, Representative cross section
showing plaque with thin fibrotic cap and a fixed thrombus in the lumen of the vessel (staining with elastin van Gieson,
15 original magnification). Panel b, Plaque cross-section with a very large lipid core (staining with elastin van Gieson,
15 original magnification). Panel c, Plaque cross-section shows a plaque rupture with plaque content erupting from
the lipid core (staining with elastin van Gieson, 50 original magnification). Panel d, Plaque cross-section shows an
intraplaque hemorrhage (staining with hematoxylin and eosin, 50 original magnification).
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the effects of individual statins were analyzed separately,
simvastatin was associated with lower PMA (P .003) and
Fig 4. Box and whisker plots show the distribution of p
surface area of all cross-sections per specimen and the t
(PMMA-9) in relation to the surface area of all cross-sect
the interquartile range (IQR) and the centerlines repres
adjacent values (
1.5  IQR).
Table II. Unadjusted associations between baseline chara
macrophage-rich area and percentage of matrix metallopro
Variable PMA 0.86%, OR (95%
Baseline characteristics
Statin therapy 0.4 (0.17-0.88)
Symptomatic stenosis 1000
Age 66 years 0.5 (0.20-1.05)
Grade of stenosis85% 1.3 (0.57-3.04)
Male sex 1.0 (0.41-2.42)
Coronary artery disease 0.6 (0.26-1.35)
Myocardial infarction 1.0 (0.36-2.79)
Peripheral vascular disease 0.7 (0.31-1.77)
Hypertension 0.6 (0.10-4.09)
Hyperlipidemia 1.2 (0.50-3.06)
Diabetes mellitus 0.7 (0.29-1.61)
BMI (per unit increase) 1.0 (0.90-1.12)
Current smoker 1.6 (0.68-3.55)
Ex-smoker 0.67 (0.24-1.86)
Alcohol abuse 1.3 (0.32-5.10)
Family history of vascular diseases 1.1 (0.48-2.44)
Plaque morphology
Plaque rupture 15.8 (1.96-127.10)
Large core 4.6 (1.37-15.14)
Giant core 3.3 (1.27-8.62)
Plaque hemorrhage 2.8 (1.05-7.26)
Thrombus 5.3 (1.08-26.18)
BMI, Body mass index; CI, confidence interval; OR, odds ratio; PMA, percen
area.
aLikelihood ratio test of heterogeneity. Values of P  .05 are significant.PMMP-9A values (P  .0009), whereas atorvastatin-treated patients had lower values for PMMP-9A (P 
.00001) but not for PMA (P  .1).
Because assumptions for multiple linear regression
tage of macrophage-rich area (PMA) in relation to the
ercentage of matrix metalloproteinase-9-positive areas
er specimen in different patient groups. Boxes represent
e median. The whiskers extend to the upper and lower
tics and plaque morphology, and percentage of
se-9 area
Pa PMMP-9A 0.16%, OR (95% CI) Pa
.02 0.1 (0.05-0.3) .0001
.0001 14.1 .0001
.06 0.7 (0.29-1.47) .3
.5 1.3 (0.57-3.04) .5
1.0 1.2 (0.51-3.0) .7
.2 1.2 (0.52-2.67) .7
1.0 0.8 (0.27-2.13) .6
.5 1.1 (0.47-2.60) .8
.6 0.6 (0.10-4.09) .6
.6 0.5 (0.21-1.32) .2
.4 1.2 (0.51-2.84) .7
1.0 1.0 (0.94-1.16) .4
.3 1.6 (0.68-3.55) .3
.4 0.88 (0.31-2.40) .8
.7 00.78 (0.20-3.11) .7
.8 0.8 (0.34-1.74) .5
.0004 15.8 (1.96-127.10) .0004
.007 2.3 (0.80-6.89) .1
.01 3.3 (1.27-8.62) .01
.03 0.9 (0.36-2.24) .8
.02 1.9 (0.51-6.91) .3
microphage-rich areas; PMMP-9A, percentage of matrix metalloproteinase-9ercen
otal p
ions p
ent thcteris
teina
CI)
tage ofanalysis were not met for the relationship between statin
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ables that categorized patients as above (1) or below (0) the
median PMA and PMMP-9A values, respectively, were
used for further analysis. Table II summarizes the results of
the unadjusted analysis of associations between baseline
variables and PMA/PMMP-9A. The serologic parameters
listed in Table I were not significantly associated with PMA
or PMMP-9A in univariable analysis; there was also no
association between all medications other than statins and
PMA or PMMP-9A.
Statin therapy, symptomatic stenosis, age older than
median age of 66 years, coronary artery disease, and hyper-
lipidemia were associated with PMA or PMMP-9A at the
P  .2 level and were therefore included in the multivari-
able models. In the final models, only statin therapy and
symptomatic stenosis were independently associated with
PMA, with odds ratios (OR) of 0.3 (95% confidence inter-
val [CI], 0.1-0.84) and 100 (95% CI not measurable),
respectively, and PMMP-9A, with ORs of 0.1 (95% CI,
0.02-0.2) and 29.7 (95% CI, 6.11-144.53), respectively.
As a last step, all baseline variables, including vascular risk
factors, serologic parameters, and medications, were added
again, individually to the model, but none of them influ-
enced the adjusted effects of statins and symptomatic ste-
nosis, nor did any of them become significant in the ad-
justed analysis at this stage. Thus, the effects of statin
therapy and symptomatic stenosis on PMA and PMMP-9A
were independent of each other and of all other variables.
When associations between morphologic features of
indirect plaque instability and PMA/PMMP-9A were as-
sessed using binary outcomes, all features were significantly
associated with PMA values above the median, and plaque
rupture and giant plaque core were associated with
PMMP-9A values above the median. These associations
remained significant after adjusting for statin therapy using
standard logistic regression analysis.
DISCUSSION
There are three important findings from the present
Table III. Associations between symptomatic stenosis, pla
No.
Symptomatic
(n  26),
No. (%)
Asymptomatic
(n  68), No.
(%) Pa
Plaque rupture 13 9 (35) 4 (6) .00
No plaque rupture 81 17 (66) 64 (94)
Large core 76 25 (96) 51 (75) .02
No large core 18 1 (4) 17 (25)
Giant core 27 13 (50) 14 (21) .00
No giant core 67 13 (50) 54 (79)
Plaque hemorrhage 25 12 (46) 13 (19) .00
No hemorrhage 69 14 (54) 55 (81)
Thrombus 11 4 (15) 7 (10) .49
No thrombus 83 22 (85) 61 (90)
IQR, Interquartile range; PMA, percentage of microphage-rich areas; PMM
aMann-Whitney U test.
b2 test.study. Our data indicate that:1. PMA and PMMP-9A are suitable markers of plaque
instability, with significantly higher values of PMA and
PMMP-9A present in symptomatic compared with
asymptomatic ICA plaques;
2. higher values of PMA and PMMP-9A are associated
with plaque rupture and giant lipid core in carotid
stenosis; and
3. treatment with therapeutic doses of statins is associated
with reduced values of PMA and PMMP-9A in ICA
plaques.
The first two of these findings confirm the generally
accepted concept of a critical association between inflam-
matory markers and instability of atherosclerotic carotid
plaques.7,25 However, the newly defined marker “giant
lipid core” seems to be a better a marker of indirect plaque
instability than previous markers such as large lipid core,
especially in combination with other markers. In earlier
studies, a large lipid core24 was found in80% of all plaque
specimens. A giant lipid core, on the other hand, was absent
in 79% of asymptomatic carotid stenosis in our study. It
thus seems that giant lipid core is a more sensitive and
specific inflammatory marker; therefore, using multiple
markers of plaque instability may be the most sensitive
methodology.
The third finding provides important new evidence on
the possible mechanism involved in the beneficial effects of
statins. Previously, important questions involved the
known dissociation between cholesterol levels and clinical
benefit of statins with regard to cerebrovascular risk and the
uncertain effect of statins on inflammatory markers in ath-
erosclerotic plaques.21,22
Previous work has shown a clear association between
inflammatory markers, plaque instability, and risk of stroke
and TIAs, whereas other studies have shown a clear associ-
ation between use of statins and reduced risk of stroke.21,26
On the grounds of these observations, it has been sug-
gested that use of statins might be associated with a reduc-
tion in inflammatory markers, but this association had not
morphology, and inflammatory markers
PMA Median (IQR) Pb PMMP-9A Median (IQR) Pb
2.32 (1.59-3.57) .0002 0.36 (0.33-0.63) .005
0.70 (0.33-1.22) 0.12 (0.03-0.45)
0.98 (0.50-1.71) .0001 0.22 (0.05-0.49) .1
0.29 (0.09-0.53) 0.07 (0.24-0.28)
1.34 (0.74-1.93) .001 0.44 (0.08-0.63) .006
0.54 (0.29-1.21) 0.11 (0.03-0.35)
1.20 (0.61-2.27) .01 0.14 (0.06-0.69) .24
0.70 (0.31-1.33) 0.18 (0.03-0.44)
1.07 (0.88-2.72) .08 0.29 (0.01-0.35) .86
0.74 (0.33-1.52) 0.15 (0.05-0.46)
, percentage of matrix metalloproteinase-9 area.que
01
5
08
P-9Apreviously been established, with available data being con-
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that use of statins is associated with a reduction in inflam-
matory markers PMA and PMMP-9A, independently of
cholesterol levels, providing important evidence support-
ing involvement of an inflammatory mechanism in the
beneficial effects of statins.
Analyzing effects of individual statins separately, simva-
statin was associated with lower PMA and PMMP-9A
values. This effect was not found in atorvastatin-treated
patients for PMA even though these patients showed lower
values for PMMP-9A. This difference might be due to a
type II error because the number of patients taking atorva-
statin was very low. Also, the duration of therapy needed for
the effect between different statins might be different. In
this context, however, it must be mentioned that Verho-
even et al22 found a significant increase of CD68-positive
cells in carotid plaques obtained from statin-treated pa-
tients that was mainly attributable to atorvastatin-treated
patients. In patients treated with atorvastatin, the increased
amount of CD68-positive cells was not associated with
increased protease activity. On the contrary, the authors
showed a dose-dependent decrease in MMP activity in the
atorvastatin group.
Statin-mediated inhibition of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase not only blocks syn-
thesis of cholesterol but also affects synthesis of isopre-
noids. These intermediates serve as lipid attachments for a
variety of intracellular signaling molecules. Reduction of
isoprenoids probably accounts for most of the pleiotropic
effects observed with statin treatment.16-18 The reduced
number of macrophages in plaques of statin-treated pa-
tients could potentially be due to downregulation of mono-
cyte adhesion molecules,27 monocyte chemoattractant
protein-1,28 or suppression of oxidized LDL-induced mac-
rophage proliferation.29
The attenuation of MMP-9 expression that we ob-
served in the plaques of statin-treated patients might have
been due to reduced macrophage content and diminished
macrophage activation. However, the magnitude of the
reduction in PMA was less than that of MMP-9 with statin
therapy, suggesting that MMP-9 expression may serve as a
better marker for plaque instability.
The nature of our study did not allow for conclusive
statements regarding the activity of macrophages and of
MMP-9. Gelatin zymography and immunoblotting was
not done because we did not want to destroy the morpho-
logic structure of the plaque to get material for this analysis.
Further, we examined morphologic features of indirect
plaque instability to look at plaque rupture, large lipid core,
surface thrombus, and intraplaque hemorrhage and corre-
lated them with the immunohistochemical staining results.
In addition to MMP-9 and macrophage content, several
other markers that may also contribute to plaque instability
have been identified.30-33
We believe that the systematic, quantitative approach
used here was critical for obtaining unambiguous data to
address this important issue. We used sophisticated image
detection and analysis to quantify macrophage infiltrationand MMP-9 expression, which we were then able to corre-
late with clinical markers and use of statins. In our study the
entire plaque was systematically sectioned and evaluated,
with each plaque yielding 200 single, high-resolution
images per patient. Immunohistochemical staining for
macrophages and MMP-9 was carefully standardized for
reproducibility, and high-resolution images were quantita-
tively analyzed, resulting in a detailed and comprehensive
analysis of the entire plaque lesion.
Among the patients studied here, the statin group
showed a significantly higher proportion with hyperlipid-
emia and hypertension. On the one hand, the median
concentrations of cholesterol, LDL, and Apo B were lower
than in the no statin group (Table I). This may indicate that
compliance was high in the statin group, but it also empha-
sizes the importance of the statin effect, in view of the
additive risk associated with hyperlipidemia and hyperten-
sion.
An important limitation of the present study was the
length of time between symptom development and immu-
nohistochemical assessment of the plaque. The median
time between the qualifying event for a symptomatic ICA
stenosis and surgery was 17.5 days. Ideally, the shortest
possible time interval would be found between the ischemic
event and the time when the plaque material is obtained.
The relatively long time in our study raises the possibility
that healing may have already started within the lesion,
which might have diminished the magnitude of the effect
that we observed.
Patients who had an ischemic event in the same carotid
territory 120 days before surgery showed values of PMA
and PMMP-9A similar to those of asymptomatic patients
who never had an ischemic event, suggesting that a symp-
tomatic ICA stenosis can lose its high-risk character. This,
and our finding that PMA decreased over days from symp-
toms, is in line with the observation that the benefit of CEA
declines after the first few weeks after acute symptoms.34
Another important limitation of the present study was
the observational study design. A randomized, placebo-
controlled design was considered not to be ethically justi-
fiable due to the ever-growing evidence that statins exert
significant plaque-stabilizing effects and that precisely
those patients with a high degree of cerebrovascular risk are
likely to benefit most from statin treatment.35-37 In addi-
tion, the beneficial effects of early CEA in patients with
symptomatic ICA stenosis have been clearly demon-
strated,34 thus precluding a study design with delayed
intervention intended to evaluate the effect of preoperative
use of a medication.
CONCLUSION
Our data provide evidence that use of statins attenuates
the inflammatory response in carotid atherosclerotic
plaques, thereby reaffirming the hypothesis, that the bene-
ficial effects of statins on cerebrovascular events is at least
mediated by the anti-inflammatory effects of statins on
atherosclerotic plaques. Thus, the data suggest an essen-
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 3 Kunte et al 521tially mechanistic link between inflammation, plaque stabil-
ity, and statin use.
We wish to thank Dr. J. Marc Simard, Department of
Neurosurgery, University ofMaryland at Baltimore, andDr
David H. Solomon, Department of Neurology, Columbia
University, New York, New York, for helpful discussion
and critical reading of the manuscript. We also thank pa-
thologists Drs Glen Kristiansen and Wilko Weichert for
helping with staining the samples and analyzing and re-
viewing morphologic analysis.
AUTHOR CONTRIBUTIONS
Conception and design: HK, NA, RR, MB, LH
Analysis and interpretation: HK, NA, MB, SM, LH
Data collection: HK, NA, RR, LH
Writing the article: HK, MB, SM, LH
Critical revision of the article: HK, NA, RR, MB, SM, LH
Final approval of the article: HK, NA, RR, MB, SM, LH
Statistical analysis: HK, MB
Obtained funding: HK, LH
Overall responsibility: HK, LH
REFERENCES
1. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR,
et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank.
Ann Neurol 1989;25:382-90.
2. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid
plaque. Stroke 2000;31:774-81.
3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation 2002;105:1135-43.
4. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;
340:115-26.
5. Bassiouny HS, Sakaguchi Y, Mikucki SA, McKinsey JF, Piano G,
Gewertz BL, et al. Juxtalumenal location of plaque necrosis and neo-
formation in symptomatic carotid stenosis. J Vasc Surg 1997;26:
585-94.
6. Carr SC, Farb A, Pearce WH, Virmani R, Yao JS. Activated inflamma-
tory cells are associated with plaque rupture in carotid artery stenosis.
Surgery 1997;122:757-63.
7. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H,
et al. Inflammation in high-grade carotid stenosis: a possible role for
macrophages and T cells in plaque destabilization. Stroke 1998;29:
1625-30.
8. Lehtonen-Smeds EM, Mayranpaa M, Lindsberg PJ, Soinne L, Saim-
anen E, Jarvinen AA, et al. Carotid plaque mast cells associate with
atherogenic serum lipids, high grade carotid stenosis and symptomatic
carotid artery disease. Results from the Helsinki carotid endarterectomy
study. Cerebrovasc Dis 2005;19:291-301.
9. Fatar M, Stroick M, Griebe M, Hennerici M. Matrix metalloproteinases
in cerebrovascular diseases. Cerebrovasc Dis 2005;20:141-51.
10. Higashikata T, Yamagishi M, Higashi T, Nagata I, Iihara K, Miyamoto
S, et al. Altered expression balance of matrix metalloproteinases and
their inhibitors in human carotid plaque disruption: Results of quanti-
tative tissue analysis using real-time RT-PCR method. Atherosclerosis
2006;185:165-72.
11. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V,
et al. Reduction of stroke incidence after myocardial infarction with
pravastatin: the Cholesterol and Recurrent Events (CARE) study. The
Care Investigators. Circulation 1999;99:216-23.
12. Prevention of cardiovascular events and death with pravastatin in pa-
tients with coronary heart disease and a broad range of initial cholesterol
levels. The Long-Term Intervention with Pravastatin in Ischaemic
Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
13. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P,
et al. Effects of atorvastatin on stroke in patients with unstable angina ornon-Q-wave myocardial infarction: a Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) substudy. Circu-
lation 2002;106:1690-5.
14. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-
lowering with simvastatin on stroke and other major vascular events in
20536 people with cerebrovascular disease or other high-risk condi-
tions. Lancet 2004;363:757-67.
15. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB,Hennerici
M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient
ischemic attack. N Engl J Med 2006;355:549-59.
16. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005;25:
1093-110.
17. Kwak BR,Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and
immunomodulatory activities of statins. Autoimmun Rev 2003;2:
332-8.
18. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl
coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;
21:1712-9.
19. AikawaM, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y,
et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses
growth of macrophages expressing matrix metalloproteinases and tissue
factor in vivo and in vitro. Circulation 2001;103:276-83.
20. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al.
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macro-
phages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
21. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J.
Pravastatin treatment increases collagen content and decreases lipid
content, inflammation, metalloproteinases, and cell death in human
carotid plaques: implications for plaque stabilization. Circulation 2001;
103:926-33.
22. Verhoeven BA, Moll FL, Koekkoek JA, van der Wal AC, de Kleijn DP,
de Vries JP, et al. Statin treatment is not associated with consistent
alterations in inflammatory status of carotid atherosclerotic plaques: a
retrospective study in 378 patients undergoing carotid endarterectomy.
Stroke 2006;37:2054-60.
23. Beneficial effect of carotid endarterectomy in symptomatic patients with
high-grade carotid stenosis. North American Symptomatic Carotid
Endarterectomy Trial Collaborators. N Engl J Med 1991;325:445-53.
24. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological
assessment of 526 symptomatic carotid plaques in relation to the nature
and timing of ischemic symptoms: the Oxford plaque study. Circulation
2006;113:2320-8.
25. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al.
Increasedmatrixmetalloproteinase-9 activity in unstable carotid plaques. A
potential role in acute plaque disruption. Stroke 2000;31:40-7.
26. AikawaM, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y,
et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses
growth of macrophages expressing matrix metalloproteinases and tissue
factor in vivo and in vitro. Circulation 2001;103:276-83.
27. Serrano CV Jr, Yoshida VM, Venturinelli ML, D’Amico E, Monteiro
HP, Ramires JA, et al. Effect of simvastatin on monocyte adhesion
molecule expression in patients with hypercholesterolemia. Atheroscle-
rosis 2001;157:505-12.
28. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez
F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neoin-
timal inflammation in a rabbit model of atherosclerosis. J Am Coll
Cardiol 1998;32:2057-64.
29. Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T,
et al. Statins suppress oxidized low density lipoprotein-induced macro-
phage proliferation by inactivation of the small G protein-p38 MAPK
pathway. J Biol Chem 2005;280:6627-33.
30. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M,
et al. Expression of tissue factor in high-grade carotid artery stenosis:
association with plaque destabilization. Stroke 2001;32:850-4.
31. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid
plaque. Stroke 2000;31:774-81.
32. Li C, Mollahan P, Baguneid MS, McMahon RF, Kumar P, Walker MG,
et al. A comparative study of neovascularisation in atherosclerotic
plaques using CD31, CD105 and TGF beta 1. Pathobiology 2006;73:
192-7.
JOURNAL OF VASCULAR SURGERY
March 2008522 Kunte et al33. Kawahara I, Kitagawa N, Tsutsumi K, Nagata I, Hayashi T, Koji T. The
expression of vascular dendritic cells in human atherosclerotic carotid
plaques. Hum Pathol 2007;38:1378-85.
34. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ.
Endarterectomy for symptomatic carotid stenosis in relation to clinical
subgroups and timing of surgery. Lancet 2004;363:915-24.
35. MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised placebo-36. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke
prevention and carotid atherosclerosis: systematic review and up-to-
date meta-analysis. Stroke 2004;35:2902-9.
37. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and
stroke prevention. Cerebrovasc Dis 2007;24:170-82.controlled trial. Lancet 2002;360:7-22. Submitted Jul 20, 2007; accepted Nov 13, 2007.
